Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin

Autor(es)

Cerda, Alvaro ^[1] ; Genvigir, Fabiana D. V. ^[1] ; Arazi, Simone S. ^[1] ; Hirata, Mario H. ^[1] ; Dorea, Egidio L. ^[2] ; Bernik, Marcia M. S. ^[2] ; Bertolami, Marcelo C. ^[3] ; Faludi, Andre A. ^[3] ; Hirata, Rosario D. C. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, BR-05508900 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Univ Hosp, BR-05508900 Sao Paulo - Brazil

^[3] Dante Pazzanese Inst Cardiol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Clinica Chimica Acta; v. 411, n. 9-10, p. 631-637, MAY 2 2010.
• Citações Web of Science: 19

Resumo

Background: The SR-BI is a key component on the cholesterol metabolism. Polymorphisms in the SR-BI gene (SCARB1) were related with variations on plasma lipoprotein profile and other risk factors for cardiovascular disease. We tested the relationship of 3 SCARB1 single nucleotide polymorphisms (SNPs) with hypercholesterolemia in a Brazilian population and whether these variants can influence lipid-lowering response to atorvastatin. Methods: c.4G>A, c.726+54C>T and c.1050C>T SNPs and serum concentrations of lipid and apolipoproteins were evaluated in 147 hypercholesterolemic (HC) and 185 normolipidemic (NL) unrelated Brazilian subjects. HC patients were treated with atorvastatin (10 mg/day/4 weeks). Results: Frequencies of SCARB1 polymorphisms were similar between the HC and NL groups (p>0.05). The T allele for c.726+54C>T was associated with higher LDL-c in NL and with higher apoB and apoB/apoAI in HC (p<0.05). HC individuals carrying c.1050C allele carriers (CC and CT genotypes) had lower change of total cholesterol, LDL-c, apoB and apoB/apoAI ratio (p<0.05) than the TT genotype carriers in response to atorvastatin. Conclusion: The SCARB1 polymorphisms are related with variations in serum lipids in the Brazilian population and c.1050C>T SNP is associated with lipid-lowering atorvastatin response. (C) 2010 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 06/06196-0 - Estudo farmacogenômico: efeitos de hipolipemiantes sobre a expressão gênica de fatores de transcrição envolvidos na regulação do colesterol
• Beneficiário: Rosario Dominguez Crespo Hirata
• Modalidade de apoio: Auxílio à Pesquisa - Regular